49 related articles for article (PubMed ID: 37055240)
1. Tumor testing and treatment patterns in veterans with metastatic castration-resistant prostate cancer.
Hung A; Candelieri D; Li Y; Alba P; Robison B; Agiri F; Perez C; Lee KM; Maxwell KN; Li W; Aggarwal H; Pridgen K; Reed SD; DuVall S; Wong YN; Lynch JA
Semin Oncol; 2023; 50(1-2):11-24. PubMed ID: 37055240
[TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer Foundation-Department of Veterans Affairs Partnership: A Model of Public-Private Collaboration to Advance Treatment and Care of Invasive Cancers.
Levine RD; Ekanayake RN; Martin AC; Dickson K; McGarrell K; Miyahira A; Campbell RS; Johnson T; Soule HR; Simons JW
Fed Pract; 2020 Aug; 37(Suppl 4):S32-S37. PubMed ID: 32908352
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer patient stratification by molecular signatures in the Veterans Precision Oncology Data Commons.
Hernandez KM; Venkat A; Elbers DC; Bihn JR; Brophy MT; Do NV; La J; Liu Q; Prokhorenkov A; Metoki-Shlubsky N; Sung FC; Paller CJ; Fillmore NR; Grossman RL
Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 38050021
[TBL] [Abstract][Full Text] [Related]
4. The Precision Oncology Program for Cancer of the Prostate (POPCaP) Network: A Veterans Affairs/Prostate Cancer Foundation Collaboration.
Montgomery B; Rettig M; Kasten J; Muralidhar S; Myrie K; Ramoni R
Fed Pract; 2020 Aug; 37(Suppl 4):S48-S53. PubMed ID: 32908353
[TBL] [Abstract][Full Text] [Related]
5. Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer.
Barata PC; Assayag J; Li B; Siu G; Niyazov A
JAMA Oncol; 2024 May; ():. PubMed ID: 38696212
[TBL] [Abstract][Full Text] [Related]
6. The flaws in assessing and reporting the toxicities of oral targeted therapies: Everolimus as an example.
Fojo T
Semin Oncol; 2023; 50(1-2):1-6. PubMed ID: 37270213
[No Abstract] [Full Text] [Related]
7. Impact of DNA damage repair alterations on prostate cancer progression and metastasis.
Lukashchuk N; Barnicle A; Adelman CA; Armenia J; Kang J; Barrett JC; Harrington EA
Front Oncol; 2023; 13():1162644. PubMed ID: 37434977
[TBL] [Abstract][Full Text] [Related]
8. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Agarwal N; Azad AA; Carles J; Fay AP; Matsubara N; Heinrich D; Szczylik C; De Giorgi U; Young Joung J; Fong PCC; Voog E; Jones RJ; Shore ND; Dunshee C; Zschäbitz S; Oldenburg J; Lin X; Healy CG; Di Santo N; Zohren F; Fizazi K
Lancet; 2023 Jul; 402(10398):291-303. PubMed ID: 37285865
[TBL] [Abstract][Full Text] [Related]
9. Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs.
Ferretti S; Mercinelli C; Marandino L; Litterio G; Marchioni M; Schips L
Res Rep Urol; 2023; 15():243-259. PubMed ID: 37396015
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.
Antonarakis ES; Park SH; Goh JC; Shin SJ; Lee JL; Mehra N; McDermott R; Sala-Gonzalez N; Fong PC; Greil R; Retz M; Sade JP; Yanez P; Huang YH; Begbie SD; Gafanov RA; De Santis M; Rosenbaum E; Kolinsky MP; Rey F; Chiu KY; Roubaud G; Kramer G; Sumitomo M; Massari F; Suzuki H; Qiu P; Zhang J; Kim J; Poehlein CH; Yu EY
J Clin Oncol; 2023 Aug; 41(22):3839-3850. PubMed ID: 37290035
[TBL] [Abstract][Full Text] [Related]
11. Investigation of Clinically Significant Molecular Aberrations in Patients with Prostate Cancer: Implications for Personalized Treatment, Prognosis and Genetic Testing.
Fountzilas E; Kouspou M; Eliades A; Papadopoulou K; Bournakis E; Goussia A; Tsiatas M; Achilleos A; Tsangaras K; Billioud G; Loizides C; Lemesios C; Kypri E; Ioannides M; Koumbaris G; Levva S; Vakalopoulos I; Paliouras A; Pervana S; Koinis F; Bumci R; Christopoulou A; Meditskou S; Psyrri A; Boukovinas I; Visvikis A; Karavasilis V; Koukoulis GK; Kotsakis A; Giannakis D; Fountzilas G; Patsalis PC
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511593
[TBL] [Abstract][Full Text] [Related]
12. Poly-ADP ribose polymerase inhibitor and androgen receptor signaling inhibitor for all comers for first-line treatment of metastatic castration-resistant prostate cancer: is gene sequencing out?
Higano CS; Cheng HH
Curr Opin Urol; 2023 Sep; 33(5):396-403. PubMed ID: 37497748
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis.
Zheng Y; Wang K; Ou Y; Hu X; Wang Z; Wang D; Li X; Ren S
Prostate Cancer Prostatic Dis; 2023 Jun; ():. PubMed ID: 37391595
[TBL] [Abstract][Full Text] [Related]
14. Adherence to hormone therapy in patients with mCRPC: psychometric validation of the A-HT questionnaire.
Iacorossi L; Gambalunga F; Piredda M; Terrenato I; Marzo C; Latina R; Notarnicola I; Bolgeo T; De Marinis MG; Carlini P
Clin Ter; 2023; 174(4):345-352. PubMed ID: 37378505
[TBL] [Abstract][Full Text] [Related]
15. [Precision oncology options in urological cancers].
Franz A; Plage H; Fendler A; Schlomm T; Kornienko K
Urologie; 2023 Jul; 62(7):696-704. PubMed ID: 37294331
[TBL] [Abstract][Full Text] [Related]
16. The Application of Radiolabeled Targeted Molecular Probes for the Diagnosis and Treatment of Prostate Cancer.
Cheng L; Yang T; Zhang J; Gao F; Yang L; Tao W
Korean J Radiol; 2023 Jun; 24(6):574-589. PubMed ID: 37271211
[TBL] [Abstract][Full Text] [Related]
17. Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data.
Swami U; Aggarwal H; Zhou M; Jiang S; Kim J; Li W; Laliberté F; Emond B; Agarwal N
Clin Genitourin Cancer; 2023 Oct; 21(5):517-529. PubMed ID: 37248148
[TBL] [Abstract][Full Text] [Related]
18. Multi-Gene Next-Generation Sequencing Panel for Analysis of
Maloberti T; De Leo A; Coluccelli S; Sanza V; Gruppioni E; Altimari A; Zagnoni S; Giunchi F; Vasuri F; Fiorentino M; Mollica V; Ferrari S; Miccoli S; Visani M; Turchetti D; Massari F; Tallini G; de Biase D
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240284
[TBL] [Abstract][Full Text] [Related]
19. Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer.
Fallara G; Robesti D; Raggi D; Montorsi F; Necchi A; Cooperberg MR; Malavaud B; Ploussard G; Martini A
Eur Urol Open Sci; 2023 Jun; 52():40-43. PubMed ID: 37182120
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibitors in metastatic prostate cancer.
Taylor AK; Kosoff D; Emamekhoo H; Lang JM; Kyriakopoulos CE
Front Oncol; 2023; 13():1159557. PubMed ID: 37168382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
